ALID (Allied) EV-to-EBIT: 0.00 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Allied EV-to-EBIT?

Allied ALID -99.80% EV-to-EBIT is 0.00 as of Jul. 19, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Allied's Enterprise Value is $0.00 Mil. Allied's EBIT for the trailing twelve months (TTM) ended in Nov. 2024 was $-3.07 Mil. Therefore, Allied's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Allied's EV-to-EBIT or its related term are showing as below:

ALID's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 15.8
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Allied's Enterprise Value for the quarter that ended in Nov. 2024 was $10.85 Mil. Allied's EBIT for the trailing twelve months (TTM) ended in Nov. 2024 was $-3.07 Mil. Allied's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Nov. 2024 was -28.26%.

Allied  (OTCPK:ALID) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Allied's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Nov. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Nov. 2024 ) =EBIT / Enterprise Value (Q: Nov. 2024 )
=-3.065/10.8460625
=-28.26 %

Allied's Enterprise Value for the quarter that ended in Nov. 2024 was $10.85 Mil.
Allied's EBIT for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allied EV-to-EBIT Related Terms

Allied EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Allied's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allied EV-to-EBIT Chart

Allied Annual Data
Trend Mar18 Mar19 Aug20 Aug21 Aug22 Aug23 Aug24
EV-to-EBIT
Get a 7-Day Free Trial -20.72 -8.70 -3.37 -3.01 -5.42

Allied Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.60 -1.16 -3.31 -5.42 -3.54

ALID vs CBDY, PLSH, STEK: EV-to-EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allied's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allied EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allied's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Allied's EV-to-EBIT falls into.


Allied EV-to-EBIT Calculation

Allied's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-3.065
=0.00

Allied's current Enterprise Value is $0.00 Mil.
Allied's EBIT for the trailing twelve months (TTM) ended in Nov. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of 0.00 mean?
Allied (ALID) has a EV-to-EBIT of 0.00 as of Jul. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Allied and its competitors.
Is Allied's EV-to-EBIT too high?
Allied's current EV-to-EBIT is 0.00.
How does Allied's EV-to-EBIT compare to CBDY and PLSH?
Allied's EV-to-EBIT of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 15.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.80, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Allied and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allied's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied stock overvalued right now?
Allied (ALID) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Allied (ALID), the current EV-to-EBIT is 0.00 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allied Business Description

Address 460 Doyle Avenue, Suite 200, Kelowna, BC, CAN, V1Y OC2
Allied Corp is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating, and producing targeted cannabinoid health solutions. The company uses an evidence-informed scientific approach to make this mission possible through cutting-edge pharmaceutical research and development, plant-based production, and the development of therapeutic products. The company operates in two segments, which include Allied and Allied Colombia. Its geographical segments consist of Colombia and Canada. The company's revenue is comprised of sales of cannabis products.